Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Arthritis Rheumatol. Author manuscript; available in PMC 2017 December 10.
Published in final edited form as:
PMCID: PMC5723399

VISTA Deficiency Accelerates the Development of Fatal Murine Lupus Nephritis



The targeting of negative checkpoint regulators as a means of augmenting antitumor immune responses is now an increasingly used and remarkably effective approach to the treatment of several human malignancies. The negative checkpoint regulator VISTA (V-domain Ig–containing suppressor of T cell activation; also known as programmed death 1 homolog or as death domain 1α) suppresses T cell responses and regulates myeloid activities. We proposed that exploitation of the VISTA pathway is a novel strategy for the treatment of human autoimmune disease, and therefore we undertook this study to determine the impact of VISTA genetic deficiency on lupus development in a lupus-prone mouse strain.


To evaluate whether genetic deficiency of VISTA affects the development of lupus, we interbred VISTA-deficient mice with Sle1.Sle3 mice, a well-characterized model of systemic lupus erythematosus (SLE).


We demonstrated that the development of proteinuria and glomerulonephritis in these mice, designated Sle1.Sle3 VISTA−/− mice, was greatly accelerated and more severe compared to that in Sle1.Sle3 and C57BL/6 VISTA−/− mice. Analysis of cells from Sle1.Sle3 VISTA−/− mice showed enhanced activation of splenic CD4+ T cells and myeloid cell populations. No increase in titers of autoantibodies was seen in Sle1.Sle3 VISTA−/− mice. Most striking was a significant increase in proinflammatory cytokines, chemokines, and interferon (IFN)–regulated genes associated with SLE, such as IFNα, IFNγ, tumor necrosis factor, interleukin-10, and CXCL10, in Sle1.Sle3 VISTA−/− mice.


This study demonstrates for the first time that loss of VISTA in murine SLE exacerbates disease due to enhanced myeloid and T cell activation and cytokine production, including a robust IFNα signature, and supports a strategy of enhancement of the immunosuppressive activity of VISTA for the treatment of human lupus.

Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease (13). SLE is characterized by a host of immunologic abnormalities, notably loss of tolerance to nuclear components and defective clearance of apoptotic cells resulting in exposure of autoantigens (4). The pathogenesis of lupus nephritis includes the production of anti–double-stranded DNA (anti-dsDNA) antibodies, immune complex (IC) deposition in the kidneys, and progressive glomerular damage (5). Treatment of lupus nephritis is generally effective but toxic, and there remains a large unmet need for potent but safe therapeutics in this disease (6).

Targeting of negative checkpoint regulators, including programmed death 1 (PD-1) and CTLA-4, as a means of augmenting antitumor immune responses in vivo is now an increasingly used and remarkably effective approach to the treatment of several malignancies in humans (7,8). In our laboratory and those of other investigators, the negative checkpoint regulator VISTA (V-domain Ig–containing suppressor of T cell activation [9,10]; also known as PD-1 homolog [11,12] or as death domain 1α [DD-1α] [13]) has been extensively characterized (9,10,12,14). VISTA is expressed on CD11bhigh myeloid cells, neutrophils, natural killer cells, and T cells (9). VISTA shares homology with PD ligand 1 and PD-1 (9,12) and can suppress T cell activation in vitro (9). Recently, VISTA was shown to affect the activities of myeloid cells as a receptor (15), and a very recent study showed involvement of VISTA in the uptake of apoptotic cells (13). These data suggest that VISTA activities could exert a profound effect on the development and progression of lupus.

We and others have reported a mild proinflammatory phenotype in VISTA−/− mice on the nonautoimmune C57BL/6 (B6) background (11,16,17), with an increase in T cell activation markers and cytokine production. A significant increase in CD11b+MHCII+ cells and myeloid dendritic cells (DCs) is seen, indicative of enhanced myeloid cell activities in the absence of VISTA (17). In contrast, offspring of VISTA−/− mice interbred with the experimental autoimmune encephalomyelitis (EAE)–susceptible strain 2D2 T cell receptor–transgenic mice (2D2 mice), where the T cell receptor is specific formyelin oligodendrocyte glycoprotein 35–55 peptide, develop severe EAE (17). Experiments involving transfer of VISTA−/− 2D2 mouse cells into recombination-activating gene 1 (RAG-1)–deficient VISTA−/− recipient mice suggest that the absence of VISTA on recipient mouse myeloid cells exacerbates the development of autoimmunity. However, in EAE, it appears that the absence of VISTA on the encephalitogenic T cells also contributes to the enhancement of disease (17). The role of VISTA in controlling autoimmunity is also apparent in a hepatitis model in which enhanced inflammation and expanded T cell responses are seen in the absence of VISTA (11). In this latter model, VISTA expression on T cells appears to play a key role in modulating disease.

Because VISTA affects the development of autoimmunity, specifically by regulating myeloid and T cell activities, studies were designed to evaluate the influence of VISTA in a murine model of lupus. Sle1.Sle2.Sle3 congenic mice have 3 susceptibility loci from NZM2410 lupus-prone mice, which were introgressed into nonautoimmune B6 mice. While tricongenic Sle1.Sle2.Sle3 mice spontaneously develop aggressive disease, bicongenic Sle1.Sle3 mice have reduced penetrance and severity of lupus nephritis (18). We show for the first time that Sle1.Sle3 mice with the genetic absence of VISTA (Sle1.Sle3 VISTA−/− mice) develop a profoundly accelerated and fatal form of lupus nephritis as compared with VISTA-intact Sle1.Sle3 mice. Extensive analysis revealed that VISTA deficiency primarily affects the myeloid and T cell compartment, imparting an up-regulation of costimulatory and activation markers and heightened proinflammatory cytokine production compared to control Sle1.Sle3 mice. These results support a strategy of exploiting the VISTA pathway for treatment of human autoimmune disease, including lupus.



B6.NZMSle1.Sle2.Sle3, (NZB × NZW)F1, and NZM2410 mice were purchased from The Jackson Laboratory, and female B6 mice were purchased from the National Cancer Institute (Frederick, MD). B6.VISTA−/− mice were bred as described previously (17). To generate Sle1.Sle3 VISTA−/− mice, male and female B6.NZMSle1.Sle2.Sle3 and VISTA−/− mice were interbred. According to instructions from the laboratory of Dr. Laurence Morel (Department of Pathology, Immunology, and Laboratory Medicine, University of Florida, Gainesville), genotyping was performed to identify Sle1 (D1Mit47, D1Mit15, D1Mit113, and D1Mit155), Sle2 (D4Mit6, D4Mit329, and D4Mit72), and Sle3 (CKMM, D7Mit157, and D7Mit40) loci. The absence of all markers for Sle2 was confirmed by genotyping. This was further confirmed by a loss of the “tan” coat color appearance. Sle1.Sle3 VISTA−/− mice were all gray. All mice were housed in the pathogen-free facility at the Geisel School of Medicine at Dartmouth.


Levels of proteinuria (in mg/dl) were recorded weekly using Chemstrip test strips (Roche Diagnostics) beginning when the mice were 6 weeks old. Body weight was also recorded at that time.


All antibodies for flow cytometry were purchased from BioLegend. These included antibodies against B220, CD3, CD4, CD8, CD11b, CD11c, CD16, CD19, CD40L, CD80, CD25, CD40, CD44, CD62L, CD86, CD69, CXCR5, I-Ab, IgG, GL7, PD-1, inducible costimulator, CTLA-4, NK1.1, Gr-1, F4/80, and CD45. To detect FoxP3+ Treg cells, we used a mouse Treg cell staining kit (eBioscience). We stained for expression of VISTA using an allophycocyanin-conjugated antibody (13F3) from our laboratory (9). For immunofluorescence staining, we used antibodies to detect IgG (Invitrogen), C3 (MP Biomedicals), F4/80, and CD11b.

Toll-like receptors (TLRs) and recombinant proteins

For in vitro stimulation assays, agonists for TLR-7 (R848; Invitrogen) and TLR-9 (CpG; Invitrogen) were used at 1 µg/ml. Lipopolysaccharide (LPS) at 10 ng/ml (Sigma-Aldrich) and interferon-α (IFNα) at 1,000 units/ml (Hycult Biotechnology) were also used.

Kidney pathology

For clinical pathology, kidneys were fixed in formalin for paraffin embedding. Sections (4 mm) were stained with hematoxylin and eosin and examined in a blinded manner by one of us (ARS).

Cytokine and chemokine analysis

Serum was collected from retroorbital eye bleeds and screened by Luminex assay. The assay was performed using a 32 Milliplex Mouse Cytokine/Chemokine Magnetic Bead Panel (Millipore), run on a Bio-Plex 200 System (Bio-Rad), and quantified using Bio-Plex Manager 6.0 software (Bio-Rad). Enzyme-linked immunosorbent assay (ELISA) kits were purchased to screen for antidsDNA antibodies (BioVendor Research and Diagnostic Products), anti-dsDNA IgG (Alpha Diagnostic), and antihistone Ig (Alpha Diagnostic).

Flow cytometric analysis

Flow cytometry was performed as previously described (9,19). Cells were acquired on a MACSQuant Analyzer 10 (Miltenyi Biotec) and analyzed using FlowJo software (Tree Star).

Kidney cell isolation

Kidney cells were obtained using a Miltenyi Biotec gentleMACS Dissociator protocol.

Immunofluorescence staining

OCT compound–embedded frozen kidneys were sectioned and stored at −80°C until processing. For staining, slides were fixed in prechilled acetone for 10 minutes in Coplin jars. Excess acetone was removed, and slides were rehydrated in phosphate buffered saline (PBS). Slides were placed in a humid box and incubated with 10% goat serum (Jackson ImmunoResearch) in PBS for 1 hour at room temperature, washed in PBS, stained with antibodies for 2 hours at room temperature, and mounted with ProLong Gold Antifade Mountant with DAPI (Life Technologies). Images were acquired on a Zeiss LSM 510 Meta Confocal Microscope and analyzed with LSM 510 Meta software.

Cell sorting

Spleens were harvested and stained with the appropriate antibodies as previously described. Myeloid cells and T cells were sorted on a BD FACSAria III (BD Biosciences).

Bone marrow–derived DCs (BMDCs) and macrophage generation

BMDCs and BM macrophages were generated as previously described (20). Macrophage colony-stimulating factor, granulocyte–macrophage colony-stimulating factor, and interleukin-4 (IL-4) were used (all at 10 ng/ml; all from R&D Systems).


Heatmaps were generated from cytokine concentrations using the heatmap.2 function in the gplots package (Various R programming tools for plotting data; R package version 2.15.0) of the R statistical programming language (R Foundation for Statistical Computing; Agglomerative hierarchical clustering (unweighted pair group method with arithmetic mean) was used to build the cytokine dendrogram, with the distance between a pair of cytokines defined as 1 − r, where r is the Pearson coefficient of correlation between the concentrations of the 2 cytokines. Row scaling was then performed for each cytokine, and Z scores were plotted as a heatmap.

Statistical analysis

Graphs were generated with GraphPad Prism software version 6. Statistical analysis was performed using Student’s unpaired t-test.


Reduced VISTA expression during active disease in Sle1.Sle3 mice

Previous studies have shown that VISTA is highly expressed in the myeloid cell compartment and at lower densities on resting T cells (9,10). In the present study, we examined VISTA expression by flow cytometry (see Supplementary Figures 1A–E, available on the Arthritis & Rheumatology web site at on cell populations in Sle1.Sle3 mice during disease progression, starting with 8-week-old premorbid mice without proteinuria and ending with 40-week-old sick mice with proteinuria (100–500 mg/dl). Age- and sex-matched B6 mice were used as controls.

The percentage of inflammatory monocytes (F4/80+Gr-1+CD11bhigh) that expressed VISTA did not differ between young and old mice. However, in Sle1.Sle3 mice with advanced disease, the percentage of inflammatory monocytes that expressed VISTA was significantly reduced (Figure 1A). In contrast to its expression on myeloid cells, VISTA expression on activated T cells declined significantly with age both in control B6 mice and in Sle1.Sle3 mice (Figure 1B). In terms of absolute numbers, a significant decline in VISTA expression on splenic inflammatory monocytes and activated T cells was seen only in older, sick Sle1.Sle3 mice (see Supplementary Figures 1F and G, As anticipated (9,10), no VISTA expression on B cells was apparent (results not shown). In summary, we identified a disease-specific reduction in VISTA expression in the inflammatory monocyte compartment of lupus-prone mice as compared to B6 controls.

Figure 1
Expression of VISTA (V-domain Ig–containing suppressor of T cell activation) is reduced during active lupus, and VISTA deficiency exacerbates proteinuria and glomerulonephritis in lupus-prone Sle1.Sle3 (Sle1, 3) mice. Spleens were harvested from ...

VISTA deficiency exacerbates proteinuria and glomerulonephritis in lupus-prone Sle1.Sle3 mice

The finding that VISTA expression on inflammatory monocytes declines as lupus progresses in Sle1.Sle3 mice led us to postulate that a genetically induced loss of VISTA expression might greatly accelerate and/or exacerbate disease. To address this, VISTA−/− mice were interbred with Sle1.Sle3 mice, and disease progression was assessed by proteinuria in age-matched B6, B6 VISTA−/−, Sle1.Sle3, and Sle1.Sle3 VISTA−/− mice. Proteinuria levels were significantly higher in Sle1.Sle3 VISTA−/− mice compared with Sle1.Sle3 or B6 VISTA−/− mice (e.g., at 20 weeks, mean ± SEM 366.7 ± 84.3 mg/dl in Sle1.Sle3 VISTA−/− mice versus 48.5 ± 16.9 mg/dl in Sle1.Sle3 mice; P = 0.04 [n = 6 mice per group]) (Figure 1C). No proteinuria was detected in B6 or B6 VISTA−/− mice at any time point. Sle1.Sle3 VISTA−/− mice had dramatically reduced survival compared to Sle1.Sle3 and control mice (Figure 1D), with all Sle1.Sle3 VISTA−/− mice dead by 25 weeks. One hundred percent of mice in all other groups, including Sle1.Sle3 mice, were alive at 48 weeks.

To determine the impact of VISTA deficiency on renal pathology, kidney sections were semiquantitatively graded for inflammation. A significant increase in the interstitial infiltrate score was found in Sle1.Sle3 VISTA−/− mice compared to Sle1.Sle3 mice (mean ± SEM 3 ± 0% versus 1.17 ± 0.4%; P = 0.02) (see Supplementary Figure 2A,, but no difference in glomerular score was detected (3 ± 0% versus 1.67 ± 0.4%, respectively). The fibrosis score was also significantly increased in Sle1.Sle3 VISTA−/− mice (0.83 ± 0.2% versus 0.17 ± 0.2%; P = 0.04). In general, the clinical pathology of kidney sections consistently showed severe glomerulonephritis in Sle1.Sle3 VISTA−/− mice compared with B6 VISTA−/− mice or Sle1.Sle3 mice (Supplementary Figure 2B). These findings demonstrate that in the absence of immunoregulatory VISTA in Sle1.Sle3 mice, the progression and severity of lupus nephritis are greatly enhanced.

To determine whether disease exacerbation observed in Sle1.Sle3 VISTA−/− mice was related to increased production of autoreactive antibodies or to their nature, titers of specific serum antibodies to dsDNA (total) (Supplementary Figure 3A), IgG antidsDNA (Supplementary Figure 3B), and histones (total) (Supplementary Figure 3C) were quantified. We detected no difference between the Sle1.Sle3 mice and the Sle1. Sle3 VISTA−/− mice. No differences were found in the frequencies of splenic activated B cells (Supplementary Figure 3D), germinal center B cells (Supplementary Figure 3E), or IgG-producing B cells (Supplementary Figure 3F) between Sle1.Sle3 VISTA−/− mice and B6 VISTA−/− or Sle1.Sle3 mice. In parallel, IC (C3/IgG) deposition was examined in kidneys, and no difference was found between kidneys from Sle1.Sle3 mice and those from Sle1.Sle3 VISTA−/− mice (Supplementary Figure 2C).

VISTA deficiency on the Sle1.Sle3 background elevates proinflammatory cytokines in the serum

To evaluate the systemic effects of VISTA deficiency within the context of the Sle1.Sle3 genotype, serum levels of cytokines and chemokines were quantified in B6, B6 VISTA−/−, Sle1.Sle3, and Sle1.Sle3 VISTA−/− mice. A significant increase in mediators associated with disease pathogenesis, including IL-10, tumor necrosis factor (TNF), IFNγ, and IL-1α, was found in Sle1.Sle3 VISTA−/− mice compared to B6, B6 VISTA−/−, or Sle1.Sle3 mice (Figure 1E). A mild proinflammatory phenotype was also noted in B6 VISTA−/− mice compared to B6 mice, as previously described (17). Thus, VISTA deficiency enhances systemic inflammation in Sle1.Sle3 mice.

Increased frequencies of activated T cells in Sle1.Sle3 VISTA−/− mice compared to Sle1.Sle3 mice

Previous studies have shown that VISTA can negatively regulate T cell proliferation and activation (9) and that T cells from VISTA−/− mice express heightened levels of activation markers (17). Splenic phenotypic analysis in our study revealed modest increases in 25-week-old Sle1.Sle3 VISTA−/− mice compared with 25-week-old Sle1.Sle3 mice, both in effector CD4+ T cells (59.3 ± 3.4% versus 49.2 ± 2.3%; P = 0.03) (Figure 2A) and in activated CD4+ T cells expressing CD69 (75.5 ± 4.5% versus 61.6 ± 3.6%; P = 0.04) (Figure 2B). No difference in CD4+ Treg cells was found (Figure 2C), but a modest increase in follicular helper T cells was found in Sle1.Sle3 VISTA−/− mice (Figure 2D).

Figure 2
T cells from Sle1.Sle3 VISTA−/− mice are chronically activated. Splenocytes were harvested from 25-week-old B6, B6 VISTA−/−, Sle1.Sle3, and Sle1.Sle3 VISTA−/− female mice (n = 6 per group). A–D, ...

Th1 and Th2 immune responses are aberrant in SLE (21). To determine whether VISTA deficiency affected T helper cell differentiation, ex vivo splenic CD3+CD4+ T cells were activated with CD3 and CD28 and screened for Th1 and Th2 cytokines. At 24 hours, IFNγ, IL-4, IL-6, IL-10, and IL-13 were significantly elevated in Sle1.Sle3 VISTA−/− mice (Figure 2E). No differences in levels of IL-2 or IL-17 were found. To determine whether this was dependent on cell differentiation, transcription factors for Th1 and Th2 differentiation were assessed, and no differences were detected (data not shown).

VISTA deficiency on the Sle1.Sle3 background up-regulates costimulatory/activation molecules and proinflammatory cytokines in the splenic myeloid compartment

We next examined changes in the splenic myeloid compartment in Sle1.Sle3 VISTA−/− mice. In parallel with changes in the T cell compartment, the percentage of splenic inflammatory monocytes was significantly higher in Sle1.Sle3 VISTA−/− mice (Figure 3A). To assess myeloid activation markers in VISTA deficiency, expression of CD80, CD40, and I-Ab was examined in splenic lymphoid DCs (CD11chighCD8highCD11bintermediate) (Figure 3B), myeloid DCs (CD11chighCD11bhighCD8low Gr-1intermediate) (Figure 3C), and macrophages (F4/80highCD11bintermediateCD11cintermediate) (Figure 3D). In all 3 groups, expression was significantly greater in Sle1.Sle3 VISTA−/− mice compared with B6 VISTA−/− or Sle1.Sle3 mice. This heightened activation status correlated functionally with increases in IL-10 production (Figure 3E) and IFNγ production (Figure 3F), but not TNF production (Figure 3G), by purified ex vivo splenic inflammatory monocytes in response to in vitro stimulation with LPS. These increases in IL-10 and IFNγ mimicked those seen previously in the serum of Sle1.Sle3 VISTA−/− mice (Figure 1E).

Figure 3
VISTA deficiency on the Sle1.Sle3 background up-regulates costimulatory/activation molecules and proinflammatory cytokines in the splenic myeloid compartment. Splenocytes were harvested from 25-week-old B6, B6 VISTA−/−, Sle1.Sle3, and ...

VISTA deficiency on the Sle1.Sle3 background enhances myeloid infiltration into nephritic kidneys

Infiltration of myeloid cell populations displaying a proinflammatory phenotype into the kidneys of mice with active nephritis has been well characterized (22). To assess whether VISTA deficiency altered the infiltration of myeloid cells into the kidneys, renal infiltrating cells were analyzed by flow cytometry as well as by immunofluorescence staining of frozen kidney specimens. Immunofluorescence staining revealed an abundance of CD11b+ and F4/80+ cells in Sle1.Sle3 VISTA−/− mice compared with Sle1.Sle3 mice (Figure 4A). In parallel, flow cytometric analysis showed a significant increase in Gr-1+ CD11b+ cells (Figure 4B).

Figure 4
VISTA deficiency exacerbates myeloid cell infiltration into the kidney. Female Sle1.Sle3 and Sle1.Sle3 VISTA−/− mice ages 25 weeks (n = 5 per group) were monitored weekly for proteinuria. A, To assess myeloid cell infiltration into the ...

Heightened proinflammatory phenotype in Sle1.Sle3 VISTA−/− mouse BMDCs

A mild inflammatory phenotype in VISTA−/− mice has been reported (17). To determine whether VISTA plays an intrinsic role in myeloid cells in addition to T cells, BMDCs and BM macrophages were generated ex vivo from BM precursors and assessed for the expression of activation markers in response to LPS stimulation. Expression of CD80, but not CD16 or I-Ab, on BMDCs was significantly increased in Sle1.Sle3 VISTA−/− mice compared with Sle1.Sle3 mice (Figure 5A). Expression of CD80 and CD40 was also increased on BM macrophages (Figure 5B). To assess whether an increased activation phenotype was associated with augmented effector function, supernatants from LPS-activated BMDC and BM macrophage cultures were screened. Levels of IL-12 (Figure 5C) and TNF (Figure 5D) were modestly yet significantly increased in BMDCs from Sle1.Sle3 VISTA−/− mice compared to those from Sle1.Sle3 mice. There was no significant increase in IL-12 production by BM macrophages (Figure 5E); however, as with BMDCs, there was a significant increase in TNF production by LPS-activated BM macrophages from Sle1.Sle3 VISTA−/− mice compared to those from Sle1.Sle3 mice (Figure 5F).

Figure 5
Heightened function of bone marrow–derived dendritic cells (BMDCs) and BM macrophages in Sle1.Sle3 VISTA−/− mice. A and B, To determine the activation status of Sle1.Sle3 VISTA−/− mouse cells characterized by CD80, ...

More robust IFN signature in Sle1.Sle3 VISTA−/− mice

In several murine models of lupus, including MRL/lpr, (NZB × NZW)F1, and Sle1.Sle2.Sle3 mice, high levels of IFNα- and IFNγ-responsive genes are expressed (2325). We examined whether VISTA deficiency exacerbates this so-called “IFN signature” in Sle1.Sle3 mice. Indeed, by ELISA, IFNα levels were elevated in the serum of Sle1.Sle3 VISTA−/− mice compared to that of Sle1.Sle3 or B6 VISTA−/− mice (Figure 6A). We next stimulated BMDCs in vitro with IFNα (Figure 6B), with R848 (which binds TLR-7) (Figure 6C), or with CpG (which binds TLR-9) (Figure 6D), and we measured the levels of CXCL10 and IFNβ (both of which are classic IFN-responsive gene products) in supernatants at 24 hours by Luminex assay. In lupus, ICs containing nuclear components are recognized by TLR-7 and TLR-9, which in part drives disease progression (26,27). In support of the notion of VISTA-mediated regulation of IFN responsiveness in this model of lupus, levels of CXCL10 and IFNβ were modestly elevated in Sle1.Sle3 VISTA−/− mice compared to Sle1.Sle3 or B6 VISTA−/− mice in response to stimulation with IFNα (Figure 6B), R848 (TLR-7) (Figure 6C), or CpG (TLR-9) (Figure 6D).

Figure 6
VISTA deficiency exacerbates IFN signature in Sle1.Sle3 mice. A, To assess levels of IFNα, serum was collected from B6, B6 VISTA−/−, Sle1.Sle3, and Sle1.Sle3 VISTA−/− female mice and tested with an IFNα ...


The data presented herein are the first to demonstrate the role of VISTA in regulating the development of murine SLE. In this study, we first showed that VISTA expression on activated CD4+ T cells is generally reduced with age, but that is not the case with inflammatory monocytes. However, VISTA expression on inflammatory monocytes was stable with age in B6 mice, but significantly reduced in nephritic mice with disease progression (Figure 1). Furthermore, a significant decline in the absolute number of splenic inflammatory monocytes and activated T cells with normal VISTA expression was seen only in older, sick Sle1.Sle3 mice and not in B6 controls (see Supplementary Figures 1F and G, At present, the factors and environmental triggers at the transcriptional and posttranscriptional levels involved in regulating VISTA expression are unclear. One study has shown that DD-1α (VISTA) is a downstream postapoptotic target of the transcription factor p53 and that expression is enhanced by genotoxic stress (13). Furthermore, we have observed heightened VISTA expression in the tumor microenvironment and in response to retinoic acid and hypoxia (Mabaera R: unpublished observations).

We then demonstrated that Sle1.Sle3 mice bred onto a VISTA-deficient background experience significantly accelerated fatal glomerulonephritis, with pronounced enhancement of the systemic autoimmune phenotype imparted by the Sle1 and Sle3 loci. Morel and Wakeland demonstrated that the combination of Sle1 and Sle3 loci results in development of systemic autoimmunity and variably penetrant, severe glomerulonephritis (28). The mortality rate in the original bicongenic Sle1.Sle3 cohort was 25% at 1 year, with 50% of all mice demonstrating proliferative glomerulonephritis on renal pathology at termination (28). In our survival cohort, the lack of VISTA dramatically worsened outcome, with all Sle1.Sle3 VISTA−/− mice dead by week 25, while 100% of Sle1.Sle3 mice were still alive at 48 weeks (Figure 2B). Highly significant increases in TNF, IL-1α, IL-10, and IFNγ were apparent in the serum of Sle1.Sle3 VISTA−/− mice compared to all other groups, suggesting a highly inflammatory systemic environment.

Investigators in our laboratory had previously shown that offspring of VISTA−/− mice interbred with 2D2 mice develop severe EAE (17). Similar to the findings in the VISTA−/− 2D2 mice, we observed increased IFNγ production by CD4+ T cells in Sle1.Sle3 VISTA−/− mice. In addition, production of IL-10 and TNF by ex vivo–stimulated CD4+ T cells harvested from Sle1.Sle3 VISTA−/− mice was also increased, the former significantly so (Figure 2E), and this may be the basis for the elevated levels of these cytokines in the serum of sick mice. Taken together, these data suggest that VISTA plays an important role in regulating autoimmunity, particularly the production of a fairly restricted number of pathogenic cytokines: IFNγ in mice with EAE and Sle1.Sle3 mice and IL-10 in Sle1.Sle3 mice. In EAE, VISTA expression is detected on both myeloid and T cells, and VISTA-deficient 2D2 mice develop severe EAE (17). Analysis of cells from the central nervous system showed an increase in IL-17A+ and IFNγ+ T cells inVISTA−/− 2D2 mice. Furthermore, experiments involving transfer of VISTA−/− 2D2 mouse cells into RAG-1–deficient VISTA−/− recipient mice suggested that the absence of VISTA on recipient mouse myeloid cells exacerbates the development of autoimmunity. Collectively, these data demonstrated a crucial role of VISTA in the myeloid and T cell compartments (17).

An increased percentage of inflammatory monocytes was found in the spleens of 25-week-old Sle1.Sle3 VISTA−/− mice compared with other groups (Figure 3A). In addition, elevated expression of multiple costimulatory/activation molecules was seen (Figures 3B–D). Furthermore, ex vivo elaboration of several proinflammatory cytokines from in vitro–stimulated inflammatory myeloid cells was found, with significant increases in IL-10 and IFNγ (Figures 3E and F) as well as a statistically nonsignificant increase in TNF (Figure 3G). This heightened inflammatory phenotype may contribute to the same elevated cytokine levels that were observed in the serum of nephritic Sle1.Sle3 VISTA−/− mice. In addition, we documented increased myeloid cell infiltration into kidneys of Sle1.Sle3 VISTA−/− mice (Figure 4) and enhanced myeloid activation in the BM (Figure 5). Cumulatively, these findings suggest that an activated myeloid compartment in the absence of VISTA contributes to the intensified disease seen in Sle1.Sle3 VISTA−/− mice.

Type I IFNs have been linked with SLE pathogenesis, the so-called “IFN signature” (29,30). Lupus patients have high levels of IFNα in their serum (31,32) and increased expression of IFN-responsive genes (29). The IFN signature has been reported in Sle1.Sle2.Sle3 mice (23). We found that IFNα levels were significantly increased in Sle1.Sle3 VISTA−/− mice compared with Sle1.Sle3 or B6 VISTA−/− mice (Figure 6A). Furthermore, in vitro stimulation of Sle1.Sle3 VISTA−/− mouse BMDCs with recombinant IFNα resulted in elevation of IFNβ and CXCL10 (Figure 6B), the latter of which correlates positively with the presence of lupus nephritis (33). We also found that CXCL10 production by Sle1.Sle3 VISTA−/− mouse BMDCs was increased by stimulation with TLR-7 (Figure 6C) and TLR-9 (Figure 6D). These findings are similar to the high levels of CXCL10 reported in TLR-7– and TLR-9–stimulated Sle1.Sle2.Sle3 mouse BMDCs (23), suggesting that VISTA may regulate myeloid activation in the BM.

A previous study has shown that IFNα interferes with the therapeutic action of CTLA-4Ig in (NZB × NZW)F1 mice (34). At present, we do not know the precise mechanisms by which VISTA deficiency contributes to heightened type I IFN in Sle1.Sle3 VISTA−/− mice. We are currently investigating which cell populations are producing these mediators as well as their implications for lupus progression. VISTA does not appear to be mediating its regulatory effects directly on the B cell compartment (see Supplementary Figure 2C, Clearly, the most striking effects are on the myeloid and T cell compartments.

In our laboratory, we have shown that an anti- VISTA monoclonal antibody, 13F3, facilitates antitumor immunity and exacerbates disease in EAE (9). Recent data have suggested that in addition to its role as a ligand on myeloid cells, VISTA can also act as a receptor on myeloid cells. For example, spontaneous cytokine production was found in monocytes from HIV-infected individuals that overexpressed VISTA. Furthermore, these monocytes were able to increase cytokine production by HIV-specific T cells (15). Investigators in our laboratory have shown that VISTA functions as a ligand on myeloid cells to suppress T cell activation through a putative VISTA receptor (9,10). Others have shown that VISTA functions as a receptor, as demonstrated by the binding of an anti-VISTA antibody to VISTA+ T cells to mediate T cell suppression (11,12).

VISTA−/− mice on the B6 background do not develop SLE, as reported by 3 independent laboratories, including our own (11,17,35). In our studies of VISTA−/− mice, 3 organs (lung, liver, and pancreas) were found to contain significant numbers of immune cell infiltrates. However, despite the presence of chronic inflammation in multiple tissues, aged (~1-year-old) VISTA−/− mice did not develop overt organ-specific autoimmune disease. This is further supported by no significant increase in serum autoantibodies and no IC deposition in the glomeruli. These findings indicate that VISTA deficiency does not result in any obvious autoimmunity in the absence of other predisposing factors. In contrast, however, a recent study has shown that 10-month-old DD-1α (VISTA)–deficient B6 mice develop spontaneous glomerulonephritis (13). At this time, it is not clear why there is a difference in disease penetrance across these VISTA−/− mice. However, this could be due to environmental factors, including animal housing, the method used for generating the deficient mice (one conditional and one gene deleted), or other as-yet-unknown reasons. Finally, the enhanced disease conferred by VISTA deficiency in Sle1.Sle3 mice despite the continued presence of other immunoregulatory molecules is similar to the exacerbated disease severity in VISTA−/− 2D2 mice (17).

In conclusion, our study demonstrates for the first time that the VISTA pathway plays a critical role in modulating the innate and adaptive immune response in the Sle1.Sle3 murine model of lupus. VISTA deficiency in this model results in an enhanced myeloid and T cell inflammatory phenotype, a more robust type I IFN signature, accelerated glomerulonephritis, and early mortality. This occurs despite the ongoing presence of other negative checkpoint regulators, which are unable to compensate for the loss of VISTA. The data presented herein establish a unique role of VISTA in regulating autoimmunity, and they support manipulation of the VISTA pathway to treat human autoimmune disease, particularly lupus. We are currently interbreeding Sle1.Sle3 mice with VISTA–conditional knockout mice. Once they become available, these mice will allow for a more specific assessment of the relative contributions of VISTA regulation of the myeloid or T cell compartments in preventing disease progression in this model. Studies are also underway to identify the counter-receptor for VISTA, which will greatly enhance our ability to dissect the role of the VISTA pathway in lupus.

Supplementary Material


The authors thank Dr. Jacqueline Channon Smith, Mr. John K. DeLong, and Mr. Gary A. Ward from the DartLab Flow Cytometry Core Facility for technical support and design of staining panels. We also thank Aarti Sanglikar from the Center for Comparative Medicine and Research. We also thank Kenneth A. Orndorff for his assistance with confocal microscopy. The authors would also like to acknowledge the Dartmouth-Hitchcock Pathology Translational Research Program for tissue processing services.

Supported by the Lupus Research Institute (award to Dr. Noelle).

Dr. Noelle has received fees in connection with VISTA and consulting fees from ImmuNext, Inc. (more than $10,000); he has received research support from ImmuNext, Inc. (more than $10,000).



All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. Drs. Ceeraz and Noelle had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Study conception and design. Ceeraz, Burns, Noelle.

Acquisition of data. Ceeraz, Sergent, Plummer, Schned, Pechenick, Noelle.

Analysis and interpretation of data. Ceeraz, Sergent, Plummer, Schned, Pechenick, Noelle.


Authors Pechenick and Noelle are employees of ImmuNext, Inc.


1. Pons-Estel GJ, Alarcón GS, Scofield L, Reinlib L, Cooper GS. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum. 2010;39:257–68. [PMC free article] [PubMed]
2. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006;54:2550–7. [PubMed]
3. Nikpour M, Urowitz MB, Ibanez D, Gladman DD. Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum. 2009;61:1152–8. [PubMed]
4. Shao WH, Cohen PL. Disturbances of apoptotic cell clearance in systemic lupus erythematosus. Arthritis Res Ther. 2011;13:202. [PMC free article] [PubMed]
5. Putterman C, Caricchio R, Davidson A, Perlman H. Systemic lupus erythematosus. Clin Dev Immunol. 2012;2012:437282. [PMC free article] [PubMed]
6. Borchers AT, Leibushor N, Naguwa SM, Cheema GS, Shoenfeld Y, Gershwin ME. Lupus nephritis: a critical review. Autoimmun Rev. 2012;12:174–94. [PubMed]
7. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23. [PMC free article] [PubMed]
8. Pardoll D, Drake C. Immunotherapy earns its spot in the ranks of cancer therapy. J Exp Med. 2012;209:201–9. [PMC free article] [PubMed]
9. Wang L, Rubinstein R, Lines JL, Wasiuk A, Ahonen C, Guo Y, et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med. 2011;208:577–92. [PMC free article] [PubMed]
10. Lines JL, Pantazi E, Mak J, Sempere LF, Wang L, O’Connell S, et al. VISTA is an immune checkpoint molecule for human T cells. Cancer Res. 2014;74:1924–32. [PMC free article] [PubMed]
11. Flies DB, Han X, Higuchi T, Zheng L, Sun J, Ye JJ, et al. Coinhibitory receptor PD-1H preferentially suppresses CD4+ T cell-mediated immunity. J Clin Invest. 2014;124:1966–75. [PMC free article] [PubMed]
12. Flies DB, Wang S, Xu H, Chen L. Cutting edge: A monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models. J Immunol. 2011;187:1537–41. [PMC free article] [PubMed]
13. Yoon KW, Byun S, Kwon E, Hwang SY, Chu K, Hiraki M, et al. Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53. Science. 2015;349:1261669. [PMC free article] [PubMed]
14. Ceeraz S, Nowak EC, Burns CM, Noelle RJ. Immune checkpoint receptors in regulating immune reactivity in rheumatic disease. Arthritis Res Ther. 2014;16:469. [PMC free article] [PubMed]
15. Bharaj P, Chahar HS, Alozie OK, Rodarte L, Bansal A, Goepfert PA, et al. Characterization of programmed death-1 homologue-1 (PD-1H) expression and function in normal and HIV infected individuals. PloS One. 2014;9:e109103. [PMC free article] [PubMed]
16. Le Mercier I, Chen W, Lines JL, Day M, Li J, Sergent P, et al. VISTA regulates the development of protective antitumor immunity. Cancer Res. 2014;74:1933–44. [PMC free article] [PubMed]
17. Wang L, le Mercier I, Putra J, Chen W, Liu J, Schenk AD, et al. Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity. Proc Natl Acad Sci U S A. 2014;111:14846–51. [PubMed]
18. Morel L, Croker BP, Blenman KR, Mohan C, Huang G, Gilkeson G, et al. Genetic reconstitution of systemic lupus erythematosus immunopathology with polycongenic murine strains. Proc Natl Acad Sci U S A. 2000;97:6670–5. [PubMed]
19. Brown CC, Esterhazy D, Sarde A, London M, Pullabhatla V, Osma-Garcia I, et al. Retinoic acid is essential for Th1 cell lineage stability and prevents transition to a Th17 cell program. Immunity. 2015;42:499–511. [PMC free article] [PubMed]
20. Zhu J, Liu X, Xie C, Yan M, Yu Y, Sobel ES, et al. T cell hyperactivity in lupus as a consequence of hyperstimulatory antigen-presenting cells. J Clin Invest. 2005;115:1869–78. [PubMed]
21. Akahoshi M, Nakashima H, Tanaka Y, Kohsaka T, Nagano S, Ohgami E, et al. Th1/Th2 balance of peripheral T helper cells in systemic lupus erythematosus. Arthritis Rheum. 1999;42:1644–8. [PubMed]
22. Bethunaickan R, Berthier CC, Ramanujam M, Sahu R, Zhang W, Sun Y, et al. A unique hybrid renal mononuclear phagocyte activation phenotype in murine systemic lupus erythematosus nephritis. J Immunol. 2011;186:4994–5003. [PMC free article] [PubMed]
23. Sriram U, Varghese L, Bennett HL, Jog NR, Shivers DK, Ning Y, et al. Myeloid dendritic cells from B6.NZM Sle1/Sle2/Sle3 lupus-prone mice express an IFN signature that precedes disease onset. J Immunol. 2012;189:80–91. [PMC free article] [PubMed]
24. Lu Q, Shen N, Li XM, Chen SL. Genomic view of IFN-α response in pre-autoimmune NZB/W and MRL/lpr mice. Genes Immun. 2007;8:590–603. [PubMed]
25. Hadj-Slimane R, Chelbi-Alix MK, Tovey MG, Bobe P. An essential role for IFN-α in the overexpression of Fas ligand on MRL/lpr lymphocytes and on their spontaneous Fas-mediated cytotoxic potential. J Interferon Cytokine Res. 2004;24:717–28. [PubMed]
26. Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Shlomchik MJ. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity. 2006;25:417–28. [PubMed]
27. Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, Akira S, et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med. 2005;202:1131–9. [PMC free article] [PubMed]
28. Morel L, Wakeland EK. Lessons from the NZM2410 model and related strains. Int Rev Immunol. 2000;19:423–46. [PubMed]
29. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003;100:2610–5. [PubMed]
30. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003;197:711–23. [PMC free article] [PubMed]
31. Ytterberg SR, Schnitzer TJ. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum. 1982;25:401–6. [PubMed]
32. Weckerle CE, Franek BS, Kelly JA, Kumabe M, Mikolaitis RA, Green SL, et al. Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis Rheum. 2011;63:1044–53. [PMC free article] [PubMed]
33. Feng X, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD, Park GS, et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum. 2006;54:2951–62. [PubMed]
34. Liu Z, Bethunaickan R, Huang W, Ramanujam M, Madaio MP, Davidson A. IFN-α confers resistance of systemic lupus erythematosus nephritis to therapy in NZB/W F1 mice. J Immunol. 2011;187:1506–13. [PMC free article] [PubMed]
35. Tang T, Li L, Tang J, Li Y, Lin WY, Martin F, et al. A mouse knockout library for secreted and transmembrane proteins. Nat Biotechnol. 2010;28:749–55. [PubMed]